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ABSTRACT 
Objective: The aim of the present study is the structure identification of UDP-N-acetyl muramate dehydrogenase and 4-hydroxy-3-methylbut-2-
enyl diphosphate reductase for 
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Methods: 
Campylobacter jejuni and designing their inhibitors using docking and simulation studies. 
Uniprot, BLAST P, Discovery Studio, Verify 3D and Maestro Schrödinger suit have been used for 
Results: The structures of UDP-N-acetylmuramic dehydrogenase and 4-hydroxy-3-methylbut-2-enyl diphosphate reductase were predicted and 
validated generating 87.80% and 85.82% score respectively. For 4-hydroxy-3-methylbut-2-enyl diphosphate reductase, HTVS resulted in 5801 
compounds while SP and XP resulted in 5781 ligands. For UDP-N-acetylmuramate dehydrogenase, HTVS resulted in 5474 compounds whereas SP 
and XP resulted in 5359 ligands.  
Conclusion: The structures of UDP-N-acetylmuramate dehydrogenase and 4-hydroxy-3-methylbut-2-enyl diphosphate reductase were detected 
and verified. The list of top 10 inhibitors was acquired that can be considered as putative and potential drug targets. 
structure identification, validation and 
docking studies. 
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INTRODUCTION 
Campylobacter jejuni is a gram negative pathogenic microorganism that 
is the principal instigator of diseases such as Campylobacteriosis which 
might lead to autoimmune disease such as Guillan–Barré syndrome [1]. 
It results in gastrointestinal ailments, disability, diarrhea, abdominal 
cramps, fever and can even lead to death. The infections caused by 
Campylobacter are increasing at a tremendous rate worldwide [2]. Its 
resistance to certain vital antibiotics has arisen as an acute public health 
matter [3]. Therefore, the need to identify novel and potential drug 
targets of C. jejuni has arisen. The availability of completed genome 
sequence of C. jejuni has bestowed the opportunity for utilizing it in 
order to identify prospective therapeutic targets [4]. Nowadays, gene 
essentiality has become a prominent benchmark for identi fication and 
prioritization of drug targets [5]. In silico analysis using the subtractive 
genomics approach for identification of essential genes facilitates in 
reducing any undesirable impact on host biology. The amalgamation of 
computational and experimental studies for gene essentiality prediction 
has led to progression in the identification of potent drug targets by 
reducing the time and resource expense. Several studies have shown 
certain genes and proteins to be essential in C. jejuni using the 
subtractive genomics approach that can be considered as putative drug 
targets [6, 7]. One such protein is 4-hydroxy-3-methylbut-2-enyl 
diphosphate reductase encoded by is pH gene [6]. It is involved in the 
metabolism of terpenoid and polyketide. Another protein UDP-N-
acetylmuramate dehydrogenase encoded by murB gene is involved in 
carbohydrate metabolism and glycan biosynthesis and metabolism [6]. 
The identification of 3D crystal structure of UDP-N-acetylmuramate 
dehydrogenase and 4-hydroxy-3-methylbut-2-enyl diphosphate 
reductase for Campylobacter jejuni will aid stipulating novel prospects 
for inventing potent inhibitors [8]. 
In this study, structure identification and docking studies of UDP-N-
acetylmuramate dehydrogenase and 4-hydroxy-3-methylbut-2-enyl 
diphosphate reductase for 
4-hydroxy-3-methylbut-2-enyl diphosphate reductase and UDP-N-
acetylmuramate dehydrogenase are enzymes encoded by ispH gene 
and murB gene, found to be essential in Campylobacter jejuni [7]. In 
this study, the structural analysis and identification of inhibitors of 
these proteins has been done in order to decipher putative drug 
targets (fig. 1). The protein sequences of 4-hydroxy-3-methylbut-2-
enyl diphosphate reductase (Q5HUR4) and UDP-N-acetylmuramate 
dehydrogenase (Q5HSB7) in Campylobacter jejuni were retrieved 
from Uniprot. 
Protein structure identification 
Further structure prediction studies were performed for the 
retrieved protein sequences. The protein structure identification 
was implemented using Discovery Studio [9]. The structural 
validation of the model was executed using Verify 3D (UCLA DOE) 
[10] in order to verify the accuracy of the overall fold/structure, 
certain stereochemical parameters and the errors present over the 
localized areas. 
Campylobacter jejuni has been carried out 
for uncovering inhibitors preceding to the identification of novel 
drug targets. 
MATERIALS AND METHODS 
Retrieval of protein targets sequences 
The structures of 4-hydroxy-3-methylbut-2-enyl diphosphate 
reductase and UDP-N-acetylmuramate dehydrogenase were 
processed using the Protein Preparation Wizard (Prep Wizard) of 
the Maestro Schrödinger suite that is a flexible molecular modeling 
environment for state-of-the-art chemical simulation analysis. 
Processing of the protein is necessary 
Preprocessing of target and active site prediction 
in order to convert the protein 
from its raw state into a state that can be used for further 
calculations using Maestro Schrödinger suite by assigning bond 
orders, adding hydrogen atoms, creating disulfide bonds, calculating 
the protonation states of all ionizable groups and optimizing the 
orientation of hydroxyl groups, Asn, Gln and His residues [11, 12]. 
The active sites of the proteins were detected by performing an 
extensive literature survey that was used further for grid generation 
[13-15]. 
Grid generation and ligand preparation 
A docking grid was generated using the Receptor Grid Generation of 
Schrödinger Suite incorporating the active sites obtained previously 
using the centroid of selected residues. The default values of the scaling 
factor and partial charge cut off were taken [16]. The ZINC Drug 
Database (Zdd) was downloaded in the sdf format. Ligand preparation 
was done using the Ligprep from the Schrödinger suite [17]. 
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High throughput virtual screening (HTVS), Standard Precision 
(SP) and Xtra Precision (XP) docking 
Docking studies were performed employing the ZINC Drug Database 
based on the active sites. The compounds were exposed to the Glide 
centered docking strategy in which the compounds were docked 
incorporating three stages which are High Throughput Virtual Screening 
(HTVS), Standard Precision (SP) and Xtra Precision (XP) [18]. Docking 
analysis lowered the low-energy conformers by the means of the 
docking filters and reduced the sampling and thoroughness of the ligand 
conformers. Glide module evaluated specific interactions, which are the 
ligand-protein interaction energies, hydrophobic interactions, hydrogen 
bonds, internal energy, π-π stacking interactions and root mean square 
deviation (RMSD) by reducing the number of false positives. D
 
ocking of 
the lead compounds was done in order to identify the probable ligands 
or protein inhibitors [19]. 
 
Fig. 1: Schematic workflow for the identification of inhibitors of 
4-hydroxy-3-methylbut-2 enyl diphosphate reductase and UDP-
N-acetylmuramate dehydrogenase of Campylobacter jejuni 
Analysis and visualization of docking results 
RESULTS AND DISCUSSION 
After performing the docking studies, the top 10 inhibitors were 
selected according to the docking score. The 3D chemical structures of 
these inhibitors were visualized using J mol interactive viewer [20]. 
UDP-N-acetylmuramate dehydrogenase yielded 44% sequence 
identity with 1UXY_A (Chain A, Murb Mutant With Ser 229 Replaced 
By Ala, Complex With Enolpyruvyl-Udp-N-Acetylglucosamine) and 
4-hydroxy-3-methylbut-2 enyl diphosphate reductase yielded 45% 
sequence identity with 3DNF_A (Chain A, Structure Of (e)-4-
hydroxy-3-methyl-but-2-enyl Diphosphate Reductase, The Terminal 
Enzyme Of The Non-mevalonate Pathway. The structures were 
predicted using Discovery Studio [21]. These were visualized using J 
mols that are represented in fig. 2. The required score for protein 
models to be validated by Verify 3D is atleast 80% [22]. Verify 3D 
resulted in an 87.80% score for UDP-N-acetylmuramate 
dehydrogenase and 85.82% score for 4-hydroxy-3-methylbut-2 enyl 
diphosphate reductase (table 1). Proteins were prepared for further 
analysis using the Protein Preparation Wizard (Prep Wizard) of the 
Maestro Schrödinger suite [23, 24] by assigning the bond orders to 
the workspace and skipping residues with existing double and triple 
bonds. None of the bond orders were changed. Hydrogens were 
added to the Workspace structure, and metals were treated. 
Disulfide bonds were created. Waters were deleted farther than 5 
angstroms from hets Optimization of H-bonds was performed. 
Certain parameters were set such as Water sampling: on, Minimize 
hydrogens of altered species: off and Use crystal symmetry: off. 
PROPKA with pH: 7.0 were used. The restrained minimization job 
was launched at RMSD: 0.3. The active sites of the proteins are 
represented in table 1. A receptor grid was generated using the 
active sites obtained from the literature available for further docking 
analysis (fig. 3) [25]. Zinc Drug Database (Zdd) is the assembly of all 
drugs approved for use and are commercially accessible as pure 
compounds. The size of this database is 3001. The ligands were 
prepared for molecular docking by assessing them through their pKa 
values, charges, tautomerization and their chiralities [26] against the 
Zdd. This database generated 6289 ligands in the mae format (table 
2). For 4-hydroxy-3-methylbut-2-enyl diphosphate reductase, HTVS 
resulted in 5801 compounds. SP docking filtered out 5781 ligands 
and XP in 5781 ligands [27, 28]. For UDP-N-acetylmuramate 
dehydrogenase, HTVS resulted in 5474 compounds, SP in 5359 
ligands and XP in 5359 ligands. The list of top 10 hits is provided in 
table 3 and 4 according to the docking score. These inhibitors can be 
used for identification of the ADME/Tox properties or 
pharmacophore modeling in future [29]. 
 
Table 1: Structure prediction, verification and active site prediction of 4-hydroxy-3-methylbut-2 enyl diphosphate reductase and UDP-N-
acetylmuramate dehydrogenase of Campylobacter jejuni 













44%  1UXY_A 87.80% 142–142, 184–184, 254–254, 229-
229, 325-325, 159-159 
4-hydroxy-3-methylbut-2-enyl 
diphosphate reductase  
ispH, lytB 
 
45%  3DNF_A 85.82% 12–12, 41-41, 74-74, 96-96, 124-124, 
167-167, 197-197, 269-269 
 
  
UDP-N-acetylmuramate dehydrogenase 4-hydroxy-3-methylbut-2-enyl diphosphate reductase 
Fig. 2: Predicted structures of protein sequences obtained from discovery studio 
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Table 2: Docking studies performed on 4-hydroxy-3-methylbut-2 enyl diphosphate reductase and UDP-N-acetylmuramate dehydrogenase 
of Campylobacter jejuni 
Proteins HTVS SP XP 
4-hydroxy-3-methylbut-2-enyl diphosphate reductase 5801 ligands 5781 ligands 5781 ligands 
UDP-N-acetylmuramate dehydrogenase  5474 ligands 5359 ligands 5359 ligands 
 
Table 3: Top 10 hits (inhibitors) obtained after docking for 4-hydroxy-3-methylbut-2-enyl diphosphate reductase 
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Table 4: Top 10 hits (inhibitors) obtained after docking for UDP-N-acetylmuramate dehydrogenase 
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UDP-N-acetylmuramate dehydrogenase 4-hydroxy-3-methylbut-2-enyl diphosphate reductase 
Fig. 3: Receptor grids generated using Schrödinger suite 
 
CONCLUSION 
Campylobacter jejuni leads to various infectious diseases such 
Campylobacteriosis. It might lead to autoimmune disorders such as 
the Guillan–Barré syndrome that can be fatal also. These infections 
are rising as a public health concern worldwide. Certain essential 
proteins such as 4-hydroxy-3-methylbut-2-enyl diphosphate 
reductase encoded by ispH gene and UDP-N-acetylmuramate de-
hydrogenase encoded by murB gene are regarded as putative drug 
targets. Therefore, in order to decipher their inhibitors, structure 
prediction and docking of UDP-N-acetylmuramate dehydrogenase and 
4-hydroxy-3-methylbut-2-enyl diphosphate against the ZINC Drug 
Database was carried out using the Discovery Studio and Maestro 
Schrödinger suite. For 4-hydroxy-3-methylbut-2-enyl diphosphate 
reductase, HTVS resulted in 5801 compounds. SP and XP resulted in 
5781 ligands. For UDP-N-acetylmuramate dehydrogenase, HTVS 
resulted in 5474 compounds, whereas SP and XP resulted in 5359 
ligands. The list of top 10 inhibitors was acquired that can be 
considered for further analysis such as the identification of the 
ADME/Tox properties, pharmacophore modeling or experimental 
studies towards the judicious construction of antibacterial drugs. 
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